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Introduction
Recurrent macrophage activation syndrome (MAS) is very
rare. Recurrent MAS should be considered secondary
cause including autoimmune disease. We experienced
recurrent MAS since toddler age without definite
etiologies. We reported a case of recurrent MAS in
16 year-old boy with HLA B27 positive juvenile anky-
losing spondylitis.
Objectives
Recurrent MAS since toddler age is considered secondary
autoimmune disease.
Methods
A 16 year-old boy was transferred from the department of
surgery due to remittent fever with pancytopenia and
splenomegaly despite improvement of septic shock after
intravenous immunoglobulin (IVIG) and antithrombin III.
He had received fistulectomy with colostomy because of
intractable perianal abscess 2 months previously. He had
been diagnosed with hemophagocytic lymphohistiocytosis
(HLH) according to HLH 1994 guideline at 3 years of age
and had been treated with IVIG. HLH recurred 3 years
later, and he was treated according to HLH 2004 protocol
for 8 weeks, and remained symptom free without mainte-
nance therapy. He relapsed again at ages 7 and 8, but we
were unable to identify any causes. He received mainte-
nance steroid treatment for 2 years after the 4th attack. He
remained symptom free until the development of back
pain and right ankle joint pain with swelling at 15 years of
age. He was diagnosed with juvenile ankylosing spondylitis
compatible with bilateral active sacroilitis and positive
HLA B27. He received naproxen with methotrexate, but
showed symptom aggravation. He showed improvement
after Etanercept, but suddenly developed intractable peria-
nal abscess.
Results
His laboratory data showed white blood cell count
1,240/μL, platelet 44,000/μL, ferritin 2,707ng/mL, trigly-
ceride 343 mg/dL, aspatate aminotransferase 238 IU/L,
alanine aminotransferase 145 IU/L, and fibrinogen
96 mg/dL. Bone marrow biopsy showed histiocytic
hyperplasia with hemophagocytosis. There was no serolo-
gic evidence of any viral infections. He was treated with
naproxen only, and improved without any other immuno-
modulatory medication. His laboratory data returned to
near normal range within 4 weeks.
Conclusion
In our case, underlying autoimmune disease should be
considered as the cause of recurrent HLH in a young
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